Zhi Li

Title: Zhi Li: Innovator in Blood-Clotting Factor VIII Fusion Protein

Introduction

Zhi Li is a prominent inventor based in Kaifeng, China. He is known for his significant contributions to the field of biotechnology, particularly in the development of blood-clotting factors. His innovative work has the potential to improve treatment options for patients with bleeding disorders.

Latest Patents

Zhi Li holds a patent for a highly glycosylated human blood-clotting factor VIII fusion protein, along with its manufacturing method and applications. This fusion protein consists of a human factor VIII, a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin β-subunit carboxyl terminal peptide, and a half-life extending portion, preferably selected from a human IgG Fc variant. The invention demonstrates a similar level of biological activity as recombinant factor VIII while extending the in vivo half-life, thereby enhancing pharmacokinetics and drug efficacy.

Career Highlights

Throughout his career, Zhi Li has worked with notable companies in the pharmaceutical industry. He has been associated with Ampsource Biopharma Shanghai Inc. and Furen Pharmaceutical Group Co., Ltd. His work in these organizations has contributed to advancements in biopharmaceuticals and therapeutic solutions.

Collaborations

Zhi Li has collaborated with several professionals in his field, including Qiang Li and Wenchen Zhu. These partnerships have fostered innovation and development in the biotechnology sector.

Conclusion

Zhi Li's contributions to the development of blood-clotting factor VIII fusion proteins highlight his role as an innovator in biotechnology. His work not only advances scientific knowledge but also has the potential to significantly impact patient care.